Fatal cases of pulmonary alveolar proteinosis: a nationwide surveillance in Japan

Y. Inoue (Osaka, Japan), E. Yamaguchi (AIchi, Japan), Y. Setoguchi (Tokyo, Japan), T. Ichiwata (Tokyo, Japan), M. Ebina (Miyagi, Japan), K. Cho (Hokkando, Japan), R. Tazawa (Niigata, Japan), H. Ishii (Tokyo, Japan), T. Kasai (Osaka, Japan), M. Akira (Osaka, Japan), T. Arai (Osaka, Japan), K. Uchida (Tokyo, Japan), H. Kida (Osaka, Japan), K. Morimoto (Nagasaki, Japan), M. Kitaichi (Wakayama, Japan), C. Sugimoto (Osaka, Japan), K. Nakata (Niigata, Japan), K. Katayama (Osaka, Japan), N. Takeuchi (Osaka, Japan), A. Matsumuro (Osaka, Japan)

Source: International Congress 2018 – Progress in rare interstitial lung diseases
Session: Progress in rare interstitial lung diseases
Session type: Oral Presentation
Number: 3783
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentation

Abstract

[Background] Pulmonary alveolar proteinosis (PAP) is a chronic rare lung disease characterized by the intra-alveolar accumulation of surfactant lipids and proteins. 10 year survival of autoimmune PAP was 89.7% (n=117, WASOG, 2017) in our institute, however, we recently reported that fibrosis develops in approximately 20% of patients with PAP in their long clinical courses, and the prognosis of them was poor (AJR. 207:544, 2016). To clarify the characteristics of fatal cases of PAP, we retrospectively analyzed the diseases cases from our Japanese cohort database. [Subject and methods] We collected 579 cases with PAP from 95 Japanese institutes, and 81 cases (14.0%) were dead. Within 81 cases, we collected the detail data from 34 cases.  [Results] 60% was autoimmune/idiopathic PAP, 34% was secondary PAP.  Median age of 34 fatal cases (65% male) was 59 (range 28-82) years old. 59% was smokers (Current and former), and  21% had dust exposure.  At the diagnosis, 21% of patients had interstitial pneumonia/pulmonary fibrosis (IP/PF), 21% had collagen vascular diseases, 18% had incfectious disease, 3% had malignant diseases.  However during the followup periods, 9% had IP/PF, 24% had incfectious disease, 24% had malignant diseases.  Causa of the death was 26% was malignantn diseases, 18% in fections, 12% was PAP, 6% IP/PF,  6% was cerebro vascular diseases.  [Conclusions] Patients with PAP had more comorbidities than previously reported. Managemnents of them would be cricial for better prognosis.  [Grant] This study was supported by the grant from AMED #17930161 (YI)



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Inoue (Osaka, Japan), E. Yamaguchi (AIchi, Japan), Y. Setoguchi (Tokyo, Japan), T. Ichiwata (Tokyo, Japan), M. Ebina (Miyagi, Japan), K. Cho (Hokkando, Japan), R. Tazawa (Niigata, Japan), H. Ishii (Tokyo, Japan), T. Kasai (Osaka, Japan), M. Akira (Osaka, Japan), T. Arai (Osaka, Japan), K. Uchida (Tokyo, Japan), H. Kida (Osaka, Japan), K. Morimoto (Nagasaki, Japan), M. Kitaichi (Wakayama, Japan), C. Sugimoto (Osaka, Japan), K. Nakata (Niigata, Japan), K. Katayama (Osaka, Japan), N. Takeuchi (Osaka, Japan), A. Matsumuro (Osaka, Japan). Fatal cases of pulmonary alveolar proteinosis: a nationwide surveillance in Japan. 3783

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Autoimmune pulmonary alveolar proteinosis complicated with infections: a nationwide surveillance study in Japan
Source: International Congress 2017 – Rare diseases
Year: 2017

Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan
Source: Eur Respir J 2011; 37: 465
Year: 2011


Pulmonary alveolar proteinosis: report of two cases
Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease
Year: 2009


Comorbid interstitial lung diseases and collagen vascular diseases in pulmonary alveolar proteinosis: a nationwide surveillance in Japan
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017

Establishment of the consecutive registration system for pulmonary alveolar proteinosis in Japan: Updated incidence, prevalence and surveillance for intractable cases
Source: International Congress 2016 – Orphan diseases I
Year: 2016

Pulmonary alveolar proteinosis, study of 29 cases
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010

Our cases with pulmonary alveolar proteinosis
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018

Surveillance of whole lung lavage for autoimmune pulmonary alveolar proteinosis in Japan
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013


Pulmonary alveolar proteinosis: from classification to therapy
Source: Breathe, 16 (2) 200018; 10.1183/20734735.0018-2020
Year: 2020



Alveolar proteinosis: epidemiology, possibilities of diagnosis
Source: Eur Respir J 2004; 24: Suppl. 48, 671s
Year: 2004

Pulmonary alveolar proteinosis and GMSCF antibodies: a case series
Source: Eur Respir J 2004; 24: Suppl. 48, 670s
Year: 2004

Pulmonary alveolar proteinosis and idiopathic pulmonary hemosiderosis
Source: International Congress 2019 – CCC Airway diseases
Year: 2019



Pulmonary alveolar proteinosis: A case report
Source: Annual Congress 2013 –Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms
Year: 2013

Call for an international survey on therapeutic lavage for pulmonary alveolar proteinosis
Source: Eur Respir J 2012; 39: 1049
Year: 2012


Clinical assessment and management of pulmonary alveolar proteinosis: the importance of a reference centre
Source: Annual Congress 2009 - Pulmonary alveolar proteinosis: clearing the Milky Way
Year: 2009


Pulmonary alveolar proteinosis
Source: Eur Respir Mon; 2009: 46: 208–224
Year: 2009

Pulmonary alveolar proteinosis
Source: Eur Respir Rev 2011; 20: 98-107
Year: 2011



Lung cysts in pulmonary alveolar proteinosis.
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018

Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide
Source: Eur Respir Rev 2015; 24: 607-620
Year: 2015